|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's range||0.6612 - 0.6612|
|52-week range||0.6612 - 0.6612|
|Beta (5Y monthly)||1.35|
|PE ratio (TTM)||N/A|
|Earnings date||09 Aug 2021 - 13 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Troubled biotech Tonix Pharmaceuticals Holding (Nasdaq:TNXP) wasn't having a bad time of it on Monday. In mid-afternoon, the shares were trading marginally higher, likely because of the announcement of a new company facility. Tonix divulged in a press release that on Tuesday, it will conduct a groundbreaking ceremony at a new manufacturing facility in southeastern Massachusetts.
Tonix Pharmaceuticals (NASDAQ: TNXP) investors are having a bad week. Hot off the heels of a devastating interim analysis from one of its late-stage clinical trials that looks all but doomed to end in failure, the stock's price has fallen well below $1. Given that its other late-stage programs target notoriously difficult-to-treat conditions, including post-traumatic stress disorder (PTSD) and Alzheimer's disease, the entire company is looking quite frail.
Shares of Tonix Pharmaceuticals (NASDAQ: TNXP) were crashing 28.3% lower as of 10:24 a.m. EDT on Monday. The big decline came after Tonix announced on Friday following the market close that it is halting enrollment in a late-stage clinical study evaluating TNX-102 SL in treating fibromyalgia. Tonix made the decision to stop enrollment in its late-stage study of TNX-102 SL after the study's Independent Data Monitoring Committee (IDMC) completed an interim analysis.